Evidence map›Paper›PMID 32524332›Full record

ArticleImmunologic research2020

Downregulation of B regulatory cells and upregulation of T helper 1 cells in children with Gaucher disease undergoing enzyme replacement therapy.

Asmaa M Zahran, Mervat A M Youssef, Engy Adel Shafik, Zeinab Albadry M Zahran, Omnia El-Badawy, Amir M Abo Elgheet, Khalid I Elsayh

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Old disease-New reflections: Gaucher, immunity, and inflammation.Journal of cellular and molecular medicine · 2024
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Asmaa M ZahranDepartment of Clinical Pathology, South Egypt Cancer Institute, Assiut, Egypt.
Mervat A M YoussefChildren's Hospital, Faculty of Medicine, Assiut University, Assiut, Egypt.
Engy Adel ShafikDepartment of Clinical Pathology, South Egypt Cancer Institute, Assiut, Egypt.
Zeinab Albadry M ZahranDepartment of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Omnia El-BadawyDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt. omniaalbadawy@aun.edu.eg.ORCID 0000-0001-8445-711X
Amir M Abo ElgheetChildren's Hospital, Faculty of Medicine, Assiut University, Assiut, Egypt.
Khalid I ElsayhChildren's Hospital, Faculty of Medicine, Assiut University, Assiut, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gaucher disease (GD) involves a broad spectrum of immunological cells, including T helper (Th) cells and regulatory B cells (Bregs), which function to resolve the immune response and inhibit excessive inflammation. This study aimed to explore T helper cells, B cells, and Bregs in GD children undergoing enzyme replacement therapy (ERT). Our study included 20 GD patients; six patients were categorized as type 1 and 14 as type 3 GD. All patients were on regular ERT. Twenty healthy children were enrolled as controls. All patients and controls were subjected to complete blood analysis, abdominal ultrasound, and flow cytometric detection of T helper cells, B cells, and Bregs. Despite undergoing ERT, CD4+ T helper lymphocytes and Bregs were still significantly lower in patients with GD compared with the controls. Th1 and B cells were more in the patients than in the healthy controls. Lower levels of Bregs were found in type 3, compared with type 1 patients. Increased platelet count was directly associated with increased levels of Bregs and lower levels of B cells. Elevated children's height was also accompanied by decreasing levels of Th1. Our results propose that ERT in GD is associated with partial improvement in immune status, and long-term ERT might be needed for the restoration of the desired immune response levels. Levels of Bregs and Th1 can be employed for monitoring improvement of immune status in GD patients undergoing ERT.

Indexed as

AdolescentB-Lymphocytes, RegulatoryB-Lymphocyte SubsetsChildDisease ProgressionEgyptEnzyme Replacement TherapyFemaleFlow CytometryGaucher DiseaseHumansImmunophenotypingMaleMonitoring, ImmunologicPhenotypeTh1 CellsB regulatory cellsERTGaucher diseaseTh1T helper cells

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.